Eylea

Selected form

Aflibercept

Method of action: Antitumour, Inhibiting Neoangiogenesis, Ophthalmologicals

Treatment option: Macular Degeneration

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eylea

Eylea is a major prescription medicine used to treat several serious, vision-threatening conditions affecting the back of the eye, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The drug is a brand name for the active ingredient aflibercept.

Quick Facts

Property	Description
Active Ingredient	Aflibercept (INN)
Form	Solution for intravitreal injection
Pharmacological Class	Vascular Endothelial Growth Factor (VEGF) Inhibitor
Manufacturer	Regeneron Pharmaceuticals (US) / Bayer AG (International)
Key Differentiating Feature	Dual blockade of VEGF-A and PlGF

Eylea contains the active ingredient aflibercept, which is a specialized recombinant fusion protein. It is classified as a Vascular Endothelial Growth Factor (VEGF) inhibitor. This means the medicine is designed to block the chemical signals that promote the growth of abnormal, leaky blood vessels in the retina, which is the underlying cause of several retinal diseases.

Specifically, aflibercept is clinically recognized for its high-affinity binding and dual-blocking action. It is designed to bind not only to VEGF-A but also to Placental Growth Factor (PlGF), a feature that distinguishes it from some other anti-VEGF agents. This dual mechanism is intended to provide broader suppression of the biological factors that cause the fluid leakage and damaging blood vessel growth.

Eylea is administered directly into the eye by a specialist as an intravitreal injection. This method ensures the medicine reaches the target tissue effectively.

Regulatory References

Aflibercept (Eylea) Review on NCBI/NIH Bookshelf

What side effects are possible with Eylea?

Possible Side Effects and Safety Information

The safety profile for Eylea (aflibercept) is based strictly on data from regulatory sources, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adverse reactions are categorized by frequency and system affected.

Ocular and Systemic Adverse Reactions

The majority of documented side effects are categorized as Eye Disorders. Frequency is classified using regulatory standards (e.g., Very Common ge 10%, Common 1% to < 10%).

Classification	Representative Side Effects
Very Common	Conjunctival hemorrhage (bleeding in the clear part of the eye).
Common	Eye pain, increased intraocular pressure (IOP), cataract, vitreous floaters, vitreous detachment, retinal hemorrhage.

Serious Safety Concerns

The official labeling highlights critical risks primarily related to the administration procedure and the drug's mechanism as a vascular growth factor inhibitor. These include:

Endophthalmitis (serious infection inside the eye) and Retinal detachment, both risks associated with the intravitreal injection procedure.
Arterial Thromboembolic Events (ATEs): A documented systemic risk that includes serious events such as nonfatal stroke, nonfatal myocardial infarction (heart attack), and vascular death.

Safety Restrictions and Special Populations

Eylea is Contraindicated in patients with an active or suspected ocular or periocular infection, active intraocular inflammation, or a known hypersensitivity to aflibercept or its inactive ingredients.

Official safety notes advise that the medicine may cause fetal harm, requiring females of reproductive potential to use effective contraception during treatment and for a specified period after the final dose. Additionally, pre-term infants treated for Retinopathy of Prematurity require extended periods of monitoring for recurrence.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Eylea (Aflibercept)

Overdose Scope

Classification	Official Regulatory Statements
Documented Overdose Presentation	The injection of an excessive volume of the product into the eye may result in an acute increase in intraocular pressure (IOP).
Physiological Systems Affected	The ocular system (specifically IOP) is affected. The cardiovascular system (potential for Arterial Thromboembolic Events) is also noted as a potential risk.
Population-Specific Notes	Simultaneous bilateral treatment may lead to increased systemic exposure. No specific differential overdose considerations are documented for hepatic or renal impairment.

Emergency Actions and Support

Action Type	Regulatory Requirement (Label-Derived Phrasing)
When Immediate Medical Help is Required	Patients must be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay. These symptoms include eye pain, eye redness, light sensitivity, or a change in vision.
Immediate Monitoring	Monitoring of intraocular pressure is required within 60 minutes following the intravitreal injection, and management must be appropriate.
Supportive Treatment	Symptomatic and supportive treatment is the official guidance for overdose management. No specific antidote is known for aflibercept.

The regulatory profile defines overdose primarily through the local effects of excess volume on the eye, specifically acute IOP elevation. Emergency response focuses on the immediate reporting and appropriate management of serious complications like endophthalmitis, as mandated by the official prescribing information, due to the critical nature of these events.

Therapeutic Uses of Eylea

What Eylea treats: main uses and benefits

The primary therapeutic uses for Eylea (aflibercept) involve stabilizing and supporting vision in conditions where symptoms are linked to heightened physiological activity in the eye. This treatment is administered via intravitreal injection to address specific issues within the retina.

The medicine is used for several serious retinal conditions, including:

Neovascular (wet) age-related macular degeneration
Diabetic macular edema
Macular edema following Retinal Vein Occlusion
Diabetic retinopathy
Retinopathy of Prematurity in preterm infants

This therapy helps manage symptoms related to central vision impairment and visual distortion caused by fluid accumulation. It is applied in clinical settings for both acute changes, such as vascular blockage, and the long-term management of chronic conditions like diabetic eye disease.

The treatment supports the maintenance of vision, assisting with functional stability when symptoms interfere with routine activities. For patients, this intervention helps manage the fluid accumulation that causes significant blurry vision and addresses the progression of vision-threatening damage. The overall goal is to contribute to improved comfort and help manage symptom fluctuations more steadily.

Quick Fact: Addressing Macular Swelling

This treatment is used to help reduce the fluid and swelling in the macula, which are key factors in acute vision loss and visual distortion across many retinal diseases.

Eligibility and Restrictions for Use

Eylea (aflibercept) is permitted only for specific patient populations as defined by regulatory authorities and is strictly prohibited for others.

Contraindications (Must Not Use)

Patients with active or suspected ocular or periocular infections (in or around the eye).
Patients experiencing active severe intraocular inflammation.
Individuals with known or suspected hypersensitivity (allergic reaction) to aflibercept or any of the inactive ingredients (excipients).

Special Population Eligibility

Population Category	Regulatory Status
Age Groups	Approved for adults for all major indications. Pediatric use is not established except for preterm infants with Retinopathy of Prematurity (ROP).
Pregnancy	Not recommended. Women of childbearing potential must use effective contraception during and for a specified period after treatment.
Lactation	Not recommended during breastfeeding.
Renal/Hepatic Impairment	No dose adjustment is typically necessary based on current data for renal or mild hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Eylea, which contains the active substance aflibercept, is primarily defined by its unique route of administration. Because the medicine is administered as a localized intravitreal injection, only minimal levels of aflibercept reach the systemic circulation. This characteristic is the basis for the regulatory finding that systemic drug-drug interactions are not anticipated.

Regulatory documentation confirms that Eylea is not expected to interact with the liver enzymes (CYP450) or drug transporters responsible for metabolizing most systemic medicines. Therefore, official labels do not list any medicinal products or substances that significantly alter the plasma concentration or clearance of aflibercept, nor does aflibercept alter the exposure of other co-administered systemic drugs.

Interaction-Related Restrictions

Due to this localized activity, the main interaction-related restrictions are focused on the immediate environment of the eye, classified as contraindications to the procedure itself:

Ocular or Periocular Infection: The medicine must not be administered if an active or suspected infection in or around the eye is present.
Intraocular Inflammation: Administration is restricted in the presence of active severe inflammation inside the eye.
Hypersensitivity: The medicine is contraindicated in patients with a known hypersensitivity to aflibercept or any of the inactive ingredients.

Official prescribing information does not document any known interactions with food, alcohol, or herbal products.

Mechanism of Action

The mechanism of aflibercept (Eylea) is centered on highly targeted ligand sequestration, addressing the underlying molecular signals responsible for pathological vessel growth and leakage.

Dual-Ligand Signal Suppression

Aflibercept functions as a soluble decoy receptor that traps Vascular Endothelial Growth Factor A (VEGF-A) and Placental Growth Factor (PlGF) with high affinity. This simultaneous neutralization prevents these two signals from activating their native receptors (VEGFR-1 and VEGFR-2) on endothelial cells, initiating a crucial blockade of the growth cascade.

Anti-Angiogenesis and Vascular Stabilization

By blocking the activation of VEGFR-2, the drug interrupts the cellular processes that drive pathological angiogenesis (abnormal vessel formation) and cause excessive vascular permeability. The resulting physiological effects are the inhibition of new vessel growth and the restoration of the integrity of the vascular barriers, which causes reduction of fluid accumulation within the central retinal architecture.

Dosage and Administration Information

How Eylea (Aflibercept) is Used

Eylea is a prescription medicine that follows a structured administration protocol. The general principle of its use involves two primary phases: an initial loading period and a subsequent maintenance phase. The treatment is characterized by its mandatory intravitreal injection route, meaning the medicine is delivered directly into the eye's vitreous humor. This procedure must be performed by a qualified physician experienced in ocular injections under strict aseptic conditions.

Official Dosing and Scheduling

Administration involves precise dosages, which vary depending on the formulation and condition. The standard dose is 2 mg of aflibercept per injection, though a higher dose of 8 mg (EYLEA HD) is also available for specific adult regimens.

Indication (Standard Dose)	Initial Dosing Frequency	Maintenance Dosing Frequency
Wet AMD	2 mg every 4 weeks for 3 doses	2 mg every 8 weeks (may extend to 12 weeks)
DME/DR	2 mg every 4 weeks for 5 injections	2 mg every 8 weeks

For the 8 mg formulation, the maintenance interval can range from every 8 weeks up to every 16 weeks after the initial 3 doses. The treatment interval may be adjusted (shortened or extended) by the physician based on the clinical response.

Procedural and Population Rules

Specific procedural rules govern the injection: the medicine is a single-use dose for one eye only, and any excess volume must be expelled from the syringe to ensure the precise prescribed amount is administered. No dose adjustment is required for patients with renal or hepatic impairment, nor is a special modification needed for older adults.

Recent Clinical Evidence

Research evidence / Overview of Studies for Eylea

The clinical understanding of Eylea (aflibercept) is based on findings from official research, primarily large, controlled studies that examine how the medicine was studied for specific eye conditions. This overview focuses on the types of research available, the patient groups studied, and what scientific sources describe about the findings, without offering any clinical guidance or recommendations.

Evidence for Use in Wet Age-Related Macular Degeneration (nAMD)

Research for wet AMD, a condition involving periods of heightened symptom activity, relied on pivotal Randomized Controlled Trials (RCTs). These studies examined how different treatment schedules compared to another standard medication. Studies monitored key metrics, specifically focusing on changes in Best-Corrected Visual Acuity (BCVA) and Central Retinal Thickness (CRT).

Clinical trial reports describe that findings documented patterns observed in the studies related to BCVA measurements and the measured changes in fluid levels over the first one to two years. Research also explored whether patterns of measured stability persisted in certain patient groups with less frequent treatments after the initial phase. However, long-term effects are not fully established, as outcomes beyond two years are often tracked through observational reports where evidence quality varies across studies.

Evidence for Use in Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

For Diabetic Macular Edema (DME), research involved large-scale RCTs that was evaluated in adults with Type 1 or Type 2 diabetes. Studies focused on measured changes in central vision (BCVA) and macular thickness (CRT). For Diabetic Retinopathy (DR) without vision-impairing DME, studies was studied to explore changes in the progression of the underlying eye disease itself, examining measured changes in the Diabetic Retinopathy Severity Score (DRSS).

Findings for DME studies documented the measured visual and anatomical outcomes over the study period. Follow-up durations were limited in some trials, and research comparing aflibercept directly against some newer, longer-acting agents is lacking.

Evidence for Use in Macular Edema Following Retinal Vein Occlusion (RVO)

Research on macular edema that occurs after a Retinal Vein Occlusion was evaluated in controlled clinical trials specific to both Central RVO and Branch RVO. These studies examined the measured changes in vision and anatomy over short-term intervals. The main outcomes research described were related to measured changes in central visual function, specifically the number of letters gained on a standardized vision chart, and the measured changes in macular fluid observed in imaging tests. The primary analysis points for efficacy follow-up durations were limited (short-term), meaning there is limited information for long-term outcomes regarding the ideal maintenance schedule.

What is Still Uncertain in the Research Landscape

Official reviews acknowledge several limitations in the research so far. Comparative evidence is lacking for aflibercept directly against all other treatments across every possible dosing schedule. Furthermore, results apply only to the populations studied, meaning findings may not fully capture outcomes for individuals with complex medical histories outside of the specific indications studied in the trials. The certainty remains low for long-term outcomes, highlighting the need for continued monitoring and research.

Key Studies & References

How should Eylea be stored and disposed of?

Eylea (aflibercept) must be stored and handled according to strict regulatory guidelines to maintain its integrity.

Storage Requirements

Condition	Specification (Official Labeling)
Temperature	Store in a refrigerator at mathbf2 C to mathbf8 C (mathbf36 F to mathbf46 F).
Protection	Keep in the original carton to protect from light. Do not freeze.
Ambient Limit	Unopened containers may be stored at room temperature (below mathbf25 C) for up to 24 hours prior to use.

Handling and Disposal

The medicine is for single-use only. It must be kept out of the reach of children. Any unused product remaining in the vial or syringe, including excess volume, must be discarded immediately after injection. All waste material and components must be disposed of in accordance with local regulations for safe pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.